Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of malignant B cells and induces antibody‐dependent cell‐mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab (20 mg/kg) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech‐Maranda, Ewa, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia‐Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C., Jaeger, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324531/
https://www.ncbi.nlm.nih.gov/pubmed/27977057
http://dx.doi.org/10.1111/bjh.14464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324531/
https://www.ncbi.nlm.nih.gov/pubmed/27977057
http://dx.doi.org/10.1111/bjh.14464

Ejemplares similares